Avacincaptad Pegol

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Age-Related Macular Degeneration

Conditions

Dry Age-Related Macular Degeneration

Trial Timeline

Jul 16, 2009 → Mar 24, 2011

About Avacincaptad Pegol

Avacincaptad Pegol is a phase 1 stage product being developed by Astellas Pharma for Dry Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT00950638. Target conditions include Dry Age-Related Macular Degeneration.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (6)

NCT IDPhaseStatus
NCT06970665ApprovedRecruiting
NCT05536297Phase 3Completed
NCT02686658Phase 2/3Completed
NCT02397954Phase 2Completed
NCT00950638Phase 1Completed
NCT00709527Phase 1Completed

Competing Products

20 competing products in Dry Age-Related Macular Degeneration

See all competitors